-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Enzalutamide in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enzalutamide in Peritoneal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enzalutamide in Peritoneal Cancer Drug Details: Enzalutamide (Xtandi) is a phenylimidazolidine...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Enzalutamide in Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enzalutamide in Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enzalutamide in Adenocarcinoma Drug Details: Enzalutamide (Xtandi) is a phenylimidazolidine derivative, acts...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Enzalutamide in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enzalutamide in Endometrial Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enzalutamide in Endometrial Cancer Drug Details: Enzalutamide (Xtandi) is a phenylimidazolidine...
-
Company Insights
Innovation and Patenting activity of U.S. Bancorp Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of U.S. Bancorp Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Company Insights
Innovation and Patenting activity of U.S. Concrete Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of U.S. Concrete Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Insights
Innovation and Patenting activity of U.S. Silica Holdings Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of U.S. Silica Holdings Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Chenodiol in Cerebrotendinous Xanthomatosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Chenodiol in Cerebrotendinous Xanthomatosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Chenodiol in Cerebrotendinous Xanthomatosis Drug Details: Chenodiol (Xenbilox, Chenix, Chenofalk) is an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cenegermin in Keratoconjunctivitis Sicca (Dry Eye)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cenegermin in Keratoconjunctivitis Sicca (Dry Eye) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cenegermin in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: Cenegermin (Oxervate)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cenegermin in Sicca Syndrome (Sjogren)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cenegermin in Sicca Syndrome (Sjogren) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cenegermin in Sicca Syndrome (Sjogren) Drug Details: Cenegermin (Oxervate) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tamibarotene in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tamibarotene in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tamibarotene in Acute Myelocytic Leukemia (AML,...